Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in NASH Phase 2
NCT02970942Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2016
- Primary completion
- Feb 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial of semaglutide in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Percentage of Participants With Non-Alcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis at 72 weeks. Started Nov 2016; status: completed.
02
Drugs
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02970942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02970942.